Literature DB >> 12402411

Cardiac involvement in systemic autoimmune diseases.

Piersandro Riboldi1, Maria Gerosa, Cristina Luzzana, Luca Catelli.   

Abstract

The heart and the vascular system are frequent and characteristic targets of several systemic autoimmune diseases, in particular Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc). In this chapter we review the classic cardiac abnormalities and the more recent data about cardiovascular involvement as part of a major disease complication determining a substantial morbidity and mortality. In addition to the classic cardiac abnormalities involving the heart structures, acute and chronic ischemic heart disease and cerebrovascular accidents are threatening clinical manifestations of SLE and RA associated to an early accelerated atherosclerosis. Immune-mediated inflammation is now recognized as an important factor involved in the pathogenesis of atherosclerosis. Ongoing clinical studies are being devised to find specific risk factors associated with systemic autoimmune diseases and/or treatment regimens. Hopefully, prophylactic measures should be available within the next few years.

Entities:  

Mesh:

Year:  2002        PMID: 12402411     DOI: 10.1385/CRIAI:23:3:247

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  83 in total

1.  Myocarditis and primary Sjögren's syndrome.

Authors:  K Yoshioka; H Tegoshi; T Yoshida; N Uoshima; Y Kasamatsu
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

Review 2.  Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome.

Authors:  J George; D Haratz; Y Shoenfeld
Journal:  Rheum Dis Clin North Am       Date:  2001-08       Impact factor: 2.670

3.  Cardiac manifestations in primary Sjögren's syndrome.

Authors:  M Gyöngyösi; G Pokorny; Z Jambrik; L Kovács; A Kovács; E Makula; M Csanády
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

4.  Cardiac involvement in rheumatoid arthritis.

Authors:  A M Nomeir; R Turner; E Watts; D Smith; G West; J Edmonds
Journal:  Ann Intern Med       Date:  1973-12       Impact factor: 25.391

5.  Doppler-echo evaluation of left ventricular diastolic filling in patient with mixed connective tissue disease.

Authors:  W H Leung; K L Wong; C P Lau; C K Wong; C H Cheng; Y T Tai
Journal:  Cardiology       Date:  1990       Impact factor: 1.869

Review 6.  The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology.

Authors:  J G Coghlan; D Mukerjee
Journal:  Curr Opin Rheumatol       Date:  2001-11       Impact factor: 5.006

7.  A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma).

Authors:  W P Follansbee; T R Miller; E I Curtiss; J E Orie; R L Bernstein; J M Kiernan; T A Medsger
Journal:  J Rheumatol       Date:  1990-05       Impact factor: 4.666

8.  The heart in rheumatoid arthritis (rheumatoid disease). A clinical and pathological study of sixty-two cases.

Authors:  W B LEBOWITZ
Journal:  Ann Intern Med       Date:  1963-01       Impact factor: 25.391

9.  Survival, prognosis, and causes of death in rheumatoid arthritis.

Authors:  D M Mitchell; P W Spitz; D Y Young; D A Bloch; D J McShane; J F Fries
Journal:  Arthritis Rheum       Date:  1986-06

10.  Myocarditis in mixed connective tissue disease: clinical and pathologic study of three cases and review of the literature.

Authors:  A D Lash; A L Wittman; F P Quismorio
Journal:  Semin Arthritis Rheum       Date:  1986-05       Impact factor: 5.532

View more
  15 in total

1.  Role of cardiovascular imaging in systemic autoimmune diseases.

Authors:  Simona Sitia; Luigi Gianturco; Livio Tomasoni; Maurizio Turiel
Journal:  World J Cardiol       Date:  2010-08-26

Review 2.  Can estrogens promote hypertension during systemic lupus erythematosus?

Authors:  Marcia Venegas-Pont; Michael J Ryan
Journal:  Steroids       Date:  2010-02-21       Impact factor: 2.668

3.  Rituximab in childhood lupus myocarditis.

Authors:  Pooja Aggarwal; Surjit Singh; Deepti Suri; Amit Rawat; Nidhi Narula; Rohit ManojKumar
Journal:  Rheumatol Int       Date:  2011-04-06       Impact factor: 2.631

4.  Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.

Authors:  Tamar Aprahamian; Ramon Bonegio; Jennifer Rizzo; Harris Perlman; David J Lefer; Ian R Rifkin; Kenneth Walsh
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 5.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

6.  Perceptions regarding a range of work-related issues and corresponding support needs of individuals with an intractable disease.

Authors:  Kumiko Imahashi; Reiko Fukatsu; Yasoichi Nakajima; Megumi Nakamura; Tateo Ito; Mariko Horigome; Yuichiro Haruna; Tatsuya Noda; Yasuto Itoyama
Journal:  Intractable Rare Dis Res       Date:  2016-08

7.  Systolic and diastolic heart function in SLE patients.

Authors:  Margaret Wislowska; D Dereń; M Kochmański; S Sypuła; J Rozbicka
Journal:  Rheumatol Int       Date:  2009-03-25       Impact factor: 2.631

8.  Statins induce the accumulation of regulatory T cells in atherosclerotic plaque.

Authors:  Xiao Meng; Kai Zhang; Jingjing Li; Mei Dong; Jianmin Yang; Guipeng An; Weidong Qin; Fei Gao; Cheng Zhang; Yun Zhang
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 9.  Estrogen in cardiovascular disease during systemic lupus erythematosus.

Authors:  Emily L Gilbert; Michael J Ryan
Journal:  Clin Ther       Date:  2014-09-04       Impact factor: 3.393

Review 10.  Cholinergic anti-inflammatory pathway and connective tissue diseases.

Authors:  Khalil Hajiasgharzadeh; Alireza Khabbazi; Ahad Mokhtarzadeh; Amir Baghbanzadeh; Zahra Asadzadeh; Elham Adlravan; Behzad Baradaran
Journal:  Inflammopharmacology       Date:  2021-06-14       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.